Exploration of novel non-purine xanthine oxidase inhibitors based on oxadiazolones by an integrated simulation study

Abstract

Xanthine oxidase (XO) is a significant target for developing novel drugs for treating with hyperuricemia and/or gout. Recently, a series of novel non-purine XO inhibitors (XOIs), namely 3-[4-alkoxy-3-H/(1-H-tetrazol-1-yl) phenyl]-1,2,4- oxadiazol-5(4H)-ones...